DFDA

Endovascular Revascularization (Angioplasty/Stenting)

Treatment for Lower Extremity Peripheral Arterial Disease

Typical Dosage: N/A

Effectiveness
85%
Safety Score
62%
Clinical Trials
3
Participants
75K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
62
DangerousModerateSafe
Treatment Details
Dosage Range
N/A
Time to Effect
Immediate to days
Treatment Duration
Single procedure, ongoing monitoring/potential re-interventions
Evidence Quality
MODERATE
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$500
Side Effect Mgmt:$200
Total Annual:$5,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$85,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$6,250
Cost per Remission
$7,143
Endovascular Revascularization (Angioplasty/Stenting) Outcomes

for Lower Extremity Peripheral Arterial Disease

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+80%
Remission Rate
+70%
Common Side Effects
Access site complications (hematoma, pseudoaneurysm)
+8%
Vessel dissection
+5%
Restenosis/Re-occlusion (requiring re-intervention)
+25%
Contrast-induced nephropathy
+2%

Sources:

wa.gov
nih.gov
escardio.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Endovascular Revascularization (Angioplasty/Stenting) in Lower Extremity Peripheral Arterial Disease

Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)

NCT01602159COMPLETEDNA
View Study
29 participants
INTERVENTIONAL
Baltimore, United States +1 more
Started: Jul 1, 2009

Registry of First-line Treatments in Patients With Critical Limb Ischemia

NCT01877252COMPLETED
View Study
1.2K participants
OBSERVATIONAL
Münster, Germany
Started: Jan 1, 2013